Introduction: Patients with gastrointestinal neuroendocrine carcinoma (GI-NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, there are a few reports about the role of amrubicin (AMR) and salvage chemotherapy for GI-NEC. This study aimed to analyze the efficacy and safety of AMR monotherapy in patients with platinum-refractory GI-NEC. Methods: We retrospectively analyzed platinum-refractory GI-NEC patients who received AMR monotherapy between April 2012 and September 2017 at the Cancer Institute Hospital. The dose of AMR administered was 30-45 mg/m2 on days 1-3 every 3-4 weeks. We evaluated the overall response rate (ORR) according to the RESICT ver1.1, progression-free survival (PFS), overall survival (OS), and adverse events by CTCAE ver 4.0. OS and PFS were estimated using the Kaplan-Meier method and compared using the log-rank test. All reported P values were the result of two-sided tests; P < 0.05 was considered significant. Results: 14 males and 3 females (median age, 65 years (range, 60-75)) were received platinum-based chemotherapy before AMR monotherapy. (cisplatin plus irinotecan (n ¼ 14, 82.3%), cisplatin plus etoposide (n ¼ 1, 5.9%), and fluoropyrimidine plus platinum (n ¼ 2, 11.8%) Primary sites of NEC included stomach (n ¼ 10, 58.8%), colorectal (n ¼ 3, 17.6%), esophagus (n ¼ 3, 17.6%), and duodenum (n ¼ 1, 5.9%). The median cycles of AMR administration were 3 (range, 1-15). The ORR rate was 5.8%, the median PFS was 2.1 months (1.4-6.9), and the median OS was 13.7 months (6.9-17.2). Grade 3/4 neutropenia occurred in 41.1% of patients and febrile neutropenia occurred in 5.8%. Other non-hematological toxicities were not severe and treatment related deaths were not observed. 11 patients received the subsequent chemotherapy after AMR and they had significantly longer OS than those who couldn't be received the subsequent chemotherapy. (17.2 months (5.9-NA) vs. 8.9 months (1.1-NA), p ¼ 0.0427). Conclusion: AMR showed minimum activity and safety when used for the treatment of platinum-refractory GI-NEC. Neutropenia was encountered as the most serious adverse event. It should be considered to perform the subsequent chemotherapy after AMR if possible. Introduction: Anal carcinoma is an uncommon diagnosis whose treatment carries risks of significant morbidity due to the complex target volume and multiple adjacent organs at risk. Intensity modulated radiation therapy (IMRT) offers the potential to reduce toxicity while maintaining or improving the dose distribution to the target volume. Our purpose was to evaluate the outcomes of our center since the implementation of IMRT in the treatment of squamous cell carcinoma (SCC) of the anal canal. Methods: Retrospective single-center study of patients with SCC of the anal canal treated with IMRT between 2011 and 2015. Overall survival (OS), disease free survival (DFS), colostomy free survival (CFS) and local control (LC) were calculated by the Kaplan-Meier method. Toxicity was evaluated according to Common Terminology Criteria for Adverse Events v4.0. Results: Thirty-five patients were included (males 78%, females 22%, median age 64 years). T stage distribution was Tx 8%, T1 6%, T2 40%, T3 40% and T4 6%. 63% had nodal involvement. 11% were HIV positive. Median follow-up time for surviving patients was 3 years (range 1-7 years). IMRT was used in all patients with median doses to the pelvis of 45 Gy and 59 Gy to the primary tumor, using a sequential boost. Most patients (95%) were treated with chemoradiation (CRT) and only 2 patients received RT alone. The most frequent chemotherapy regimen was 5-fluoracil and mytomycin C (94%). Median overall treatment time was 44 days. Three patients (9%) had a treatment break and one patient did not complete treatment due to severe acute toxicity. Thirty-two patients (91%) had complete response. Three patients had persistent disease and three patients developed local recurrence. These patients had abdominoperineal resection (APR), except one who refused surgery. Three-year LC was 82%. Three patients (9%) developed distant metastases as the site of first failure. Three-year OS, DFS and CFS were 84, 77% and 84%, respectively. On univariate analysis, age, sex, T stage, HIV status or nodal disease had no impact on the outcomes. Grade 3 acute skin toxicity was observed in 13 patients (37%) and one patient had grade 4 toxicity. Grades 1-2 gastrointestinal (GI) toxicity occurred in 14 patients (40%) and grade 3 toxicity in one patient. Genitourinary (GU) grade 1 acute toxicity was observed in 6 patients (17%). Major late GI toxicity (grade 3-4) was reported in 2 patients (6%) and grade 2 in 7 patients (20%). There was no relevant late skin or GU toxicity. Conclusion: Chemoradiation with IMRT achieves good clinical outcomes and low treatment-related morbidity with minor treatment interruptions and acceptable late sequelae. The small sample size may explain the lack of impact of the tested variables on univariate analysis and requires longer follow-up of our patients. patients with measurable disease (68.3%), the objective response rate 19) and there was no significant difference between primary tumor sites a median follow-up duration of 28.2 months (95% CI 23.8-31.5), the on-free survival (PFS) and overall survival (OS) were 6.3 months and 12.1 months (95% CI 10.6-12.9), respectively. In multivariate gender (female versus male, hazard ratio HR 0.73), baseline CA 19-9 level normal, HR 1.31), baseline CEA level (elevated versus normal, HR disease (versus locally advanced disease, HR 1.82), poor performance 0-1, HR 1.35), and measurable disease by RECIST criteria (versus non-1.40) were significantly associated with a poorer OS (all p < 0.05).
retrospective analysis found comparable efficacy outcomes to the prognostic factors identified here may help to predict clinical outfuture clinical trials for advanced BTC.
-line chemotherapy for advanced biliary tract cancer after of the gemcitabine-platinum combination: A single center e H ty School of Medicine Department of Medical Oncology, y Few data are available on second-line chemotherapy (CT2) for advanced biliary tract cancer (ABTC). The aim of this retrospective study was to describe the CT2 regimens used, the response rates, and the outcomes of patients treated with various CT2 regimens. Methods: Patients who received CT2 for ABTC at Bülent Ecevit University Oncology Institute after the failure of the gemcitabine-platinum combination were retrospectively studied. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method. Cox models were used for multivariate analyses. Results: Among 142 patients who received first-line chemotherapy (CT1) for ABTC, 96 received CT2: 5-fluorouracil (5-FU) and irinotecan (n ¼ 30), 5-FU and oxaliplatin (n ¼ 25), 5-FU and cisplatin (n ¼ 16), 5-FU or capecitabine (n ¼ 25). Among the 60 assessable patients, there were 7 partial responses and 17 stabilizations. After a median follow-up of 23.4 months, the median PFS and OS were 3.3 and 7.0 months, respectively. There was no significant difference in PFS or OS between CT2 regimens. Fluoropyrimidine-based doublet chemotherapy was not superior to fluoropyrimidine alone in terms of OS and PFS. In a multivariate analysis, a performance status of 0 to 1, disease control with CT1, a carbohydrate antigen 19-9 (CA 19-9) level 300 IU/mL, and age <50 years were significantly associated with longer PFS and OS. Conclusion: CT2 might provide disease control for selected patients with ABTC after the failure of gemcitabine-platinum, but the prognosis remains poor. No particular regimen seems superior to others. 
